Cormorant Asset Management’s Kindred Biosciences, Inc. KIN Stock Holding History

Cormorant Asset Management’s Portfolio KIN Stock Details KIN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-328,497	Closed	-$1.71M	–	94
2015 Q3	$1.71M	Hold	328,497	–	–	0.27%	65
2015 Q2	$2.24M	Hold	328,497	–	–	0.3%	61
2015 Q1	$2.35M	Sell	328,497 -21,503	-6%	-$148K	0.36%	55
2014 Q4	$2.61M	Hold	350,000	–	–	0.4%	52
2014 Q3	$3.24M	Buy	350,000 +250,000	+250%	+$3.38M	0.67%	41
2014 Q2	$1.86M	Buy	+100,000	New	+$1.7M	0.49%	48

Other funds holding KIN

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GCM

Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Cormorant Asset Management's KIN Position: Q4 2015 in Review

Cormorant Asset Management sold out of Kindred Biosciences, Inc. (KIN) in Q4 2015, closing a stake of 328,497 shares — an estimated $1.71M sold.

Cormorant Asset Management first reported a position in KIN in Q2 2014 and held it in 6 quarters. The position peaked at $3.24M in Q3 2014. 50 funds tracked by Wall St. Rank hold KIN as of Q4 2015.

Cormorant Asset Management reported no remaining Kindred Biosciences, Inc. position as of Q4 2015 after selling out during the quarter.
Cormorant Asset Management sold 328,497 Kindred Biosciences, Inc. shares in Q4 2015, an estimated $1.71M.
Cormorant Asset Management first reported a position in Kindred Biosciences, Inc. in Q2 2014 and held it in 6 quarters.
Cormorant Asset Management's Kindred Biosciences, Inc. position peaked at $3.24M in Q3 2014.
50 funds tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q4 2015.

Based on Cormorant Asset Management's 13F filing for Q4 2015, filed 16 Feb 2016.